ASCO® 2023 Insights: "Phase 1/2 TRIDENT-1 Trial - Intracranial and Systemic Efficacy of Repotrectinib in Advanced ROS1+ NSCLC & CNS Mets"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Jessica Lin
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Jessica Lin
Login to view comments.
Click here to Login
Videos